| Photoactivatable CRISPR-Cas9 for optogenetic genome editing Y Nihongaki, F Kawano, T Nakajima, M Sato Nature biotechnology 33 (7), 755-760, 2015 | 673 | 2015 |
| CRISPR-Cas9-based photoactivatable transcription system Y Nihongaki, S Yamamoto, F Kawano, H Suzuki, M Sato Chemistry & biology 22 (2), 169-174, 2015 | 361 | 2015 |
| CRISPR–Cas9-based photoactivatable transcription systems to induce neuronal differentiation Y Nihongaki, Y Furuhata, T Otabe, S Hasegawa, K Yoshimoto, M Sato Nature methods 14 (10), 963-966, 2017 | 166 | 2017 |
| Very fast CRISPR on demand Y Liu, R Zou, Y Nihongaki, S He, S Razavi, B Wu, T Ha Biophysical Journal 118 (3), 29a, 2020 | 149 | 2020 |
| A split CRISPR–Cpf1 platform for inducible genome editing and gene activation Y Nihongaki, T Otabe, Y Ueda, M Sato Nature chemical biology 15 (9), 882-888, 2019 | 83 | 2019 |
| Rapidly reversible manipulation of molecular activity with dual chemical dimerizers YC Lin, Y Nihongaki, TY Liu, S Razavi, M Sato, T Inoue Angewandte Chemie International Edition 52 (25), 6450-6454, 2013 | 59 | 2013 |
| Genetically engineered photoinducible homodimerization system with improved dimer-forming efficiency Y Nihongaki, H Suzuki, F Kawano, M Sato ACS chemical biology 9 (3), 617-621, 2014 | 51 | 2014 |
| Emerging Approaches for Spatiotemporal Control of Targeted Genome with Inducible CRISPR-Cas9. Y Nihongaki, T Otabe, M Sato Analytical chemistry 90 (1), 429-439, 2017 | 39 | 2017 |
| Control of adipogenic differentiation in mesenchymal stem cells via endogenous gene activation using CRISPR-Cas9 Y Furuhata, Y Nihongaki, M Sato, K Yoshimoto ACS synthetic biology 6 (12), 2191-2197, 2017 | 30 | 2017 |
| Autonomy declared by primary cilia through compartmentalization of membrane phosphoinositides SC Phua, Y Nihongaki, T Inoue Current opinion in cell biology 50, 72-78, 2018 | 15 | 2018 |
| Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene M Sato, Y Nihongaki US Patent 11,390,860, 2022 | 13 | 2022 |
| Discovery of the Hedgehog Pathway Inhibitor Pipinib that Targets PI4KIIIß L Kremer, E Hennes, A Brause, A Ursu, L Robke, HT Matsubayashi, ... Angewandte Chemie International Edition 58 (46), 16617-16628, 2019 | 11 | 2019 |
| A molecular trap inside microtubules probes luminal access by soluble proteins Y Nihongaki, HT Matsubayashi, T Inoue Nature chemical biology 17 (8), 888–895, 2021 | 9 | 2021 |
| Growth and site-specific organization of micron-scale biomolecular devices on living mammalian cells S Jia, SC Phua, Y Nihongaki, Y Li, M Pacella, Y Li, AM Mohammed, S Sun, ... Nature communications 12 (1), 5729, 2021 | 8 | 2021 |
| Defunctionalizing intracellular organelles such as mitochondria and peroxisomes with engineered phospholipase A/acyltransferases S Watanabe, Y Nihongaki, K Itoh, T Uyama, S Toda, S Watanabe, T Inoue Nature communications 13 (1), 4413, 2022 | 3 | 2022 |
| Growth and site-specific organization of micro-scale bimolecular devices on living cells RB Schulman, S Jia, SC Phua, Y Nihongaki, Y Li, M Pacella, Y Li, ... US Patent App. 18/003,462, 2023 | | 2023 |
| Split CPF1 Protein M Sato, T Otabe, Y Nihongaki US Patent App. 17/290,317, 2022 | | 2022 |
| A Split CRISPR–Cpf1 Platform for Inducible Gene Activation T Otabe, Y Nihongaki, M Sato Epigenomics: Methods and Protocols, 229-240, 2022 | | 2022 |
| Optical Control of Genome Editing by Photoactivatable Cas9 T Otabe, Y Nihongaki, M Sato Mammalian Cell Engineering: Methods and Protocols, 225-233, 2021 | | 2021 |
